메뉴 건너뛰기




Volumn 36, Issue 1, 2014, Pages 70-85

Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection

Author keywords

Adherence; Clinical trial; HIV prevention; Microbicides; PrEP

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DAPIVIRINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MICROBICIDE; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

EID: 84899071026     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-013-9861-1     Document Type: Review
Times cited : (44)

References (58)
  • 1
    • 79551672781 scopus 로고    scopus 로고
    • UNAIDS. Available from: Geneva: joint united nations programme on HIV/AIDS. Accessed 25 Mar 2013
    • UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2012. Available from: Geneva: joint united nations programme on HIV/AIDS. Accessed 25 Mar 2013.
    • Global Report: UNAIDS Report on the Global AIDS Epidemic 2012
  • 2
    • 58149131254 scopus 로고    scopus 로고
    • Age-disparate and intergenerational sex in southern Africa: The dynamics of hypervulnerability
    • Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. AIDS. 2008;22(Suppl 4):S17-25.
    • (2008) AIDS , vol.22 , Issue.SUPPL. 4
    • Leclerc-Madlala, S.1
  • 5
    • 84868153362 scopus 로고    scopus 로고
    • Available from Silver Spring, MD Accessed 19 July 2012
    • US Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available from Silver Spring, MD 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Accessed 19 July 2012.
    • (2012) FDA Approves First Drug for Reducing the Risk of Sexually Acquired HIV Infection
  • 6
    • 84859722634 scopus 로고    scopus 로고
    • What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples
    • Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, Psaros C, et al. What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J AIDS. 2012;59(5):463-8.
    • (2012) J AIDS , vol.59 , Issue.5 , pp. 463-468
    • Ware, N.C.1    Wyatt, Ma.2    Haberer, J.E.3    Baeten, J.M.4    Kintu, A.5    Psaros, C.6
  • 7
    • 84879023679 scopus 로고    scopus 로고
    • Adherence support approaches in biomedical HIV prevention trials: Experiences, insights and future directions from four multisite prevention trials
    • Amico KR, Mansoor LE, Corneli A, Torjesen K, van der Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143-55.
    • (2013) AIDS Behav , vol.17 , Issue.6 , pp. 2143-2155
    • Amico, K.R.1    Mansoor, L.E.2    Corneli, A.3    Torjesen, K.4    Van Der Straten, A.5
  • 9
    • 77955133374 scopus 로고    scopus 로고
    • Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials
    • Ferrer RA, Morrow KM, Fisher WA, Fisher JD. Toward an information-motivation-behavioral skills model of microbicide adherence in clinical trials. AIDS Care. 2010;22(8):997-1005.
    • (2010) AIDS Care , vol.22 , Issue.8 , pp. 997-1005
    • Ferrer, R.A.1    Morrow, K.M.2    Fisher, W.A.3    Fisher, J.D.4
  • 10
    • 84865653865 scopus 로고    scopus 로고
    • HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention
    • Roberts ET, Matthews DD. HIV and chemoprophylaxis, the importance of considering social structures alongside biomedical and behavioral intervention. Soc Sci Med. 2012;75(9):1555-61.
    • (2012) Soc Sci Med , vol.75 , Issue.9 , pp. 1555-1561
    • Roberts, E.T.1    Matthews, D.D.2
  • 11
    • 84870295000 scopus 로고    scopus 로고
    • State of the science of adherence in pre-exposure prophylaxis and microbicide trials
    • Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J AIDS. 2012;61(4):490-8.
    • (2012) J AIDS , vol.61 , Issue.4 , pp. 490-498
    • Muchomba, F.M.1    Gearing, R.E.2    Simoni, J.M.3    El-Bassel, N.4
  • 12
    • 84864505868 scopus 로고    scopus 로고
    • Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    • Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
    • (2012) N Engl J Med , vol.367 , Issue.5 , pp. 399-410
    • Baeten, J.M.1    Donnell, D.2    Ndase, P.3    Mugo, N.R.4    Campbell, J.D.5    Wangisi, J.6
  • 16
    • 84879000125 scopus 로고    scopus 로고
    • Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial
    • Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-90.
    • (2013) Lancet , vol.381 , Issue.9883 , pp. 2083-2090
    • Choopanya, K.1    Martin, M.2    Suntharasamai, P.3    Sangkum, U.4    Mock, P.A.5    Leethochawalit, M.6
  • 19
    • 84865779923 scopus 로고    scopus 로고
    • Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in african men who have sex with men and female sex workers
    • doi 10.1371/journal.pone.0033103
    • Mutua G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in african men who have sex with men and female sex workers. PLoS ONE. 2012;7(4). doi 10.1371/journal.pone.0033103.
    • (2012) PLoS ONE , vol.7 , Issue.4
    • Mutua, G.1    Sanders, E.2    Mugo, P.3    Anzala, O.4    Haberer, J.E.5    Bangsberg, D.6
  • 21
    • 78650549662 scopus 로고    scopus 로고
    • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    • Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
    • (2010) N Engl J Med , vol.363 , Issue.27 , pp. 2587-2599
    • Grant, R.M.1    Lama, J.R.2    Anderson, P.L.3    McMahan, V.4    Liu, A.Y.5    Vargas, L.6
  • 22
    • 44349126694 scopus 로고    scopus 로고
    • SAVVY® (C31G) gel for prevention of HIV infection in women: A phase 3, double-blind, randomized, placebo-controlled trial in Ghana
    • doi:10.71/journal.pone.0001312
    • Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, et al. SAVVY® (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE. 2007;2(12):e1312. doi:10.71/journal.pone.0001312.
    • (2007) PLoS ONE , vol.2 , Issue.12
    • Peterson, L.1    Nanda, K.2    Opoku, B.K.3    Ampofo, W.K.4    Owusu-Amoako, M.5    Boakye, A.Y.6
  • 27
    • 0026684234 scopus 로고
    • Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes
    • Kreiss J, Ngugi E, Holmes K, Ndinya-Achola J, Waiyaki P, Roberts PL, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268(4):477-82.
    • (1992) JAMA , vol.268 , Issue.4 , pp. 477-482
    • Kreiss, J.1    Ngugi, E.2    Holmes, K.3    Ndinya-Achola, J.4    Waiyaki, P.5    Roberts, P.L.6
  • 28
    • 79954804509 scopus 로고    scopus 로고
    • Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women
    • Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, et al. Safety and effectiveness of BufferGel and 0.5 % PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25(7):957-66.
    • (2011) AIDS , vol.25 , Issue.7 , pp. 957-966
    • Abdool Karim, S.S.1    Richardson, B.A.2    Ramjee, G.3    Hoffman, I.F.4    Chirenje, Z.M.5    Taha, T.6
  • 29
    • 77958104207 scopus 로고    scopus 로고
    • PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial
    • McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.Lancet. 2010;376(9749):1329-37.
    • (2010) Lancet , vol.376 , Issue.9749 , pp. 1329-1337
    • McCormack, S.1    Ramjee, G.2    Kamali, A.3    Rees, H.4    Crook, A.M.5    Gafos, M.6
  • 30
    • 57049091723 scopus 로고    scopus 로고
    • Efficacy of carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial
    • Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977-87.
    • (2008) Lancet , vol.372 , Issue.9654 , pp. 1977-1987
    • Skoler-Karpoff, S.1    Ramjee, G.2    Ahmed, K.3    Altini, L.4    Plagianos, M.G.5    Friedland, B.6
  • 31
    • 48249154985 scopus 로고    scopus 로고
    • Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission
    • Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. New Engl J Med. 2008;359(5):463-72.
    • (2008) New Engl J Med , vol.359 , Issue.5 , pp. 463-472
    • Van Damme, L.1    Govinden, R.2    Mirembe, F.M.3    Guedou, F.4    Solomon, S.5    Becker, M.L.6
  • 32
    • 0032552228 scopus 로고    scopus 로고
    • A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases
    • Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339(8):504-10.
    • (1998) N Engl J Med , vol.339 , Issue.8 , pp. 504-510
    • Roddy, R.E.1    Zekeng, L.2    Ryan, K.A.3    Tamoufe, U.4    Weir, S.S.5    Wong, E.L.6
  • 33
    • 0034974386 scopus 로고    scopus 로고
    • Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: A randomized clinical trial
    • Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28(7):394-400.
    • (2001) Sex Transm Dis , vol.28 , Issue.7 , pp. 394-400
    • Richardson, B.A.1    Lavreys, L.2    Martin Jr., H.L.3    Stevens, C.E.4    Ngugi, E.5    Mandaliya, K.6
  • 34
    • 0037190597 scopus 로고    scopus 로고
    • Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial
    • Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360(9338):971-7.
    • (2002) Lancet , vol.360 , Issue.9338 , pp. 971-977
    • Van Damme, L.1    Ramjee, G.2    Alary, M.3    Vuylsteke, B.4    Chandeying, V.5    Rees, H.6
  • 35
    • 41849087248 scopus 로고    scopus 로고
    • SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled trial in Nigeria
    • doi:10.371/journal.pone.0001474
    • Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008;3(1):e1474. doi:10.371/journal.pone. 0001474.
    • (2008) PLoS ONE , vol.3 , Issue.1
    • Feldblum, P.J.1    Adeiga, A.2    Bakare, R.3    Wevill, S.4    Lendvay, A.5    Obadaki, F.6
  • 36
    • 57049159412 scopus 로고    scopus 로고
    • Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: Results of a phase III trial in Nigeria
    • doi:10.1371/journal.pone.0003784
    • Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE. 2008;3(11):e3784. doi:10.1371/journal.pone.0003784.
    • (2008) PLoS ONE , vol.3 , Issue.11
    • Halpern, V.1    Ogunsola, F.2    Obunge, O.3    Wang, C.H.4    Onyejepu, N.5    Oduyebo, O.6
  • 37
    • 77955930318 scopus 로고    scopus 로고
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    • Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329(5996):1168-74.
    • (2010) Science , vol.329 , Issue.5996 , pp. 1168-1174
    • Abdool Karim, Q.1    Abdool Karim, S.S.2    Frohlich, J.A.3    Grobler, A.C.4    Baxter, C.5    Mansoor, L.E.6
  • 40
    • 84868474359 scopus 로고    scopus 로고
    • RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate
    • Anton PA, Cranston RD, Kashuba A, Hendrix CW, Bumpus NN, Richardson-Harman N, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012;28(11):1412-21.
    • (2012) AIDS Res Hum Retroviruses , vol.28 , Issue.11 , pp. 1412-1421
    • Anton, P.A.1    Cranston, R.D.2    Kashuba, A.3    Hendrix, C.W.4    Bumpus, N.N.5    Richardson-Harman, N.6
  • 45
    • 80052962337 scopus 로고    scopus 로고
    • Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa
    • Williams BG, Abdool Karim SS, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J AIDS. 2011; 58(2):207-10.
    • (2011) J AIDS , vol.58 , Issue.2 , pp. 207-210
    • Williams, B.G.1    Abdool Karim, S.S.2    Karim, Q.A.3    Gouws, E.4
  • 46
    • 84866283847 scopus 로고    scopus 로고
    • Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men
    • doi: 10.1126/scitranslmed.3004006
    • Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and preexposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4(151):151ra25. doi: 10.1126/scitranslmed.3004006.
    • (2012) Sci Transl Med , vol.4 , Issue.151
    • Anderson, P.L.1    Glidden, D.V.2    Liu, A.3    Buchbinder, S.4    Lama, J.R.5    Guanira, J.V.6
  • 47
    • 84860014826 scopus 로고    scopus 로고
    • Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention
    • van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.
    • (2012) AIDS , vol.26 , Issue.7
    • Van Der Straten, A.1    Van Damme, L.2    Haberer, J.E.3    Bangsberg, D.R.4
  • 48
    • 84899057996 scopus 로고    scopus 로고
    • PrEP has high efficacy for HIV-1 prevention among higher-risk HIV-1 serodiscordant couples: A subgroup analysis from the Partners PrEP Study
    • Kahle E, Donnell D, James H, Thomas K, John-Stewart G, Nakku-Joloba E, et al. PrEP has high efficacy for HIV-1 prevention among higher-risk HIV-1 serodiscordant couples: a subgroup analysis from the Partners PrEP Study. J Int Aids Soc. 2012;15:138-9.
    • (2012) J Int Aids Soc , vol.15 , pp. 138-139
    • Kahle, E.1    Donnell, D.2    James, H.3    Thomas, K.4    John-Stewart, G.5    Nakku-Joloba, E.6
  • 49
    • 79960372412 scopus 로고    scopus 로고
    • Drug concentrations following topical and oral antiretroviral preexposure prophylaxis: Implications for HIV prevention in women
    • Abdool Karim SS, Kashuba A, Werner L, Abdool Karim Q. Drug concentrations following topical and oral antiretroviral preexposure prophylaxis: Implications for HIV prevention in women. Lancet. 2011; 378:279-81.
    • (2011) Lancet , vol.378 , pp. 279-281
    • Abdool Karim, S.S.1    Kashuba, A.2    Werner, L.3    Abdool Karim, Q.4
  • 51
    • 84880513142 scopus 로고    scopus 로고
    • Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand
    • doi: 10.1080/09540121.2012.748871
    • Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2012; doi: 10.1080/09540121.2012.748871.
    • (2012) AIDS Care
    • Tangmunkongvorakul, A.1    Chariyalertsak, S.2    Amico, K.R.3    Saokhieo, P.4    Wannalak, V.5    Sangangamsakun, T.6
  • 52
    • 77953733741 scopus 로고    scopus 로고
    • A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda
    • Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, Okong P, et al. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Trans Infect. 2010;86(3):222-6.
    • (2010) Sex Trans Infect , vol.86 , Issue.3 , pp. 222-226
    • Kamali, A.1    Byomire, H.2    Muwonge, C.3    Bakobaki, J.4    Rutterford, C.5    Okong, P.6
  • 54
    • 84899078402 scopus 로고    scopus 로고
    • Safety and acceptability of coitally dependent use of 1% tenofovir over 6 months of use
    • Abstract No. 655
    • Hillier SL. Safety and acceptability of coitally dependent use of 1% tenofovir over 6 months of use. Abstract No. 655. Microbicides 2008 New Delhi, India; 2008.
    • (2008) Microbicides 2008 New Delhi, India
    • Hillier, S.L.1
  • 55
    • 84873858944 scopus 로고    scopus 로고
    • MTN-001: Randomized pharmacokinetic crossover study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments
    • doi:10.1371/journal.pone.0055013
    • Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, et al. MTN-001: randomized pharmacokinetic crossover study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS ONE. 2013;8(1):e55013. doi:10.1371/journal.pone.0055013.
    • (2013) PLoS ONE , vol.8 , Issue.1
    • Hendrix, C.W.1    Chen, B.A.2    Guddera, V.3    Hoesley, C.4    Justman, J.5    Nakabiito, C.6
  • 56
    • 84880192830 scopus 로고    scopus 로고
    • Adherence and acceptability in MTN 001: A randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women
    • Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, Salata R, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013;17(2):737-47.
    • (2013) AIDS Behav , vol.17 , Issue.2 , pp. 737-747
    • Minnis, A.M.1    Gandham, S.2    Richardson, B.A.3    Guddera, V.4    Chen, B.A.5    Salata, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.